Skip to main content
. 2014 Jul 17;9(8):1386–1392. doi: 10.2215/CJN.10471013

Table 3.

Course of PLA2R antibody during therapy in PLA2R-related disease

Variable MMF (n=15) CP (n=18) P Value
Negative after 2 mo 4/9 11/13 0.05
Negative after 6 mo 6/8 13/13 0.06
Negative after 12 mo 8/15 16/18 0.02

Values are expressed as number of negative samples out of total available samples. MMF, mycophenolate mofetil; CP, cyclophosphamide.